Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BYL719, Cetuximab, and Cisplatin in Transorally Resectable, HPV-Associated Oropharyngeal Squamous Cell Carcinoma
NCT02298595Phase 2Withdrawn
- Start
- Aug 2016
- Primary completion
- Aug 2019
- Modality
- Small Molecules
01
Overview
Phase 2 trial of alpelisib in oropharyngeal squamous cell carcinoma (OPSCC) (3 arms). Primary endpoint: Complete clinico-radiologic response of primary tumor following induction therapy. Planned start Aug 2016; status: withdrawn.
02
Drugs
alpelisib
03
Conditions
oropharyngeal squamous cell carcinoma (OPSCC)
Beyond the preview
Go deeper on NCT02298595.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02298595.